Your browser doesn't support javascript.
loading
The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trial.
Malthaner, Richard A; Yu, Edward; Sanatani, Michael; Lewis, Debra; Warner, Andrew; Dar, A Rashid; Yaremko, Brian P; Bierer, Joel; Palma, David A; Fortin, Dalilah; Inculet, Richard I; Fréchette, Eric; Raphael, Jacques; Gaede, Stewart; Kuruvilla, Sara; Younus, Jawaid; Vincent, Mark D; Rodrigues, George B.
Afiliação
  • Malthaner RA; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Yu E; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Sanatani M; Medical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Lewis D; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Warner A; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Dar AR; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Yaremko BP; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Bierer J; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Palma DA; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Fortin D; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Inculet RI; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Fréchette E; Department of Oncology, Divisions of Thoracic Surgery and Surgical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Raphael J; Medical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Gaede S; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Kuruvilla S; Medical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Younus J; Medical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Vincent MD; Medical Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
  • Rodrigues GB; Radiation Oncology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.
Thorac Cancer ; 13(13): 1898-1915, 2022 07.
Article em En | MEDLINE | ID: mdl-35611396
ABSTRACT

BACKGROUND:

We compared the health-related quality of life (HRQOL) in patients undergoing trimodality therapy for resectable stage I-III esophageal cancer.

METHODS:

A total of 96 patients were randomized to standard neoadjuvant cisplatin and 5-fluorouracil chemotherapy plus radiotherapy (neoadjuvant) followed by surgical resection or adjuvant cisplatin, 5-fluorouracil, and epirubicin chemotherapy with concurrent extended volume radiotherapy (adjuvant) following surgical resection.

RESULTS:

There was no significant difference in the functional assessment of cancer therapy-esophageal (FACT-E) total scores between arms at 1 year (p = 0.759) with 36% versus 41% (neoadjuvant vs. adjuvant), respectively, showing an increase of ≥15 points compared to pre-treatment (p = 0.638). The HRQOL was significantly inferior at 2 months in the neoadjuvant arm for FACT-E, European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-OG25), and EuroQol 5-D-3 L in the dysphagia, reflux, pain, taste, and coughing domains (p < 0.05). Half of patients were able to complete the prescribed neoadjuvant arm chemotherapy without modification compared to only 14% in the adjuvant arm (p < 0.001). Chemotherapy related adverse events of grade ≥2 occurred significantly more frequently in the neoadjuvant arm (100% vs. 69%, p < 0.001). Surgery related adverse events of grade ≥2 were similar in both arms (72% vs. 86%, p = 0.107). There were no 30-day mortalities and 2% vs. 10% 90-day mortalities (p = 0.204). There were no significant differences in either overall survival (OS) (5-year 35% vs. 32%, p = 0.409) or disease-free survival (DFS) (5-year 31% vs. 30%, p = 0.710).

CONCLUSION:

Trimodality therapy is challenging for patients with resectable esophageal cancer regardless of whether it is given before or after surgery. Newer and less toxic protocols are needed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Terapia Neoadjuvante Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Esofágicas / Terapia Neoadjuvante Idioma: En Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Canadá